The US has undergone a substantial shift in public policy and societal attitudes toward cannabis in the past 25 years. Although illegal at the federal level, cannabis or its constituents have been legalized in Washington DC and 11 states for recreational use and 33 states for medical use. This Viewpoint provides the perspective of a researcher conducting controlled investigations of cannabis as a drug of abuse and a potential therapeutic amid these societal shifts. The goal is to describe some of the barriers to research and provide recommendations to bridge the gap between societal use of cannabis and its empirical study.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Haney M. Perspectives on Cannabis Research—Barriers and Recommendations. JAMA Psychiatry. 2020;77(10):994–995. doi:10.1001/jamapsychiatry.2020.1032
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: